Company: STAA
Filing Date: 2025-09-24
Form Type: DFAN14A
Source: 0001213900-25-091197
Chunk: 17

Company: STAAR SURGICAL CO
Filing Date: 2025-09-24
Form: DFAN14A
Chunk 17
---
 of her business ties with Alcon to her fellow directors, and that was just two days before the Merger Agreement was signed. ½ǐoc¾koldc»s ½ko"ld Yoǐc “ AUAIN½fi ” ǐkc F»o®oscd c»gc» We have been a proud stockholder of the Company for more than three decades, and we would be pleased to continue to own a large portion of the Company and support its continued recovery and future growth. We understand that the Company recently faced some near - term challenges related to inventory and tariffs, but the Company’s reduced revenue over a few quarters is not, in our view, a fundamental issue, nor do we believe it is likely to persist. On the Company’s earnings call in May 2025, the Company’s CEO proclaimed that “better days are ahead” 30 for the Company. We agree. Over the last few months, the Company has taken actions to meaningfully reduce expenses and has been working with its distributors to manage inventory levels and mitigate the impact of tariffs. 31 With ICL demand in China “getting stronger,” 32 we believe the Company will quickly return to revenue growth and accelerated profitability which, in turn, we expect to drive greater value for stockholders. As STAAR’s largest stockholder, if the Proposed Merger is defeated — as we believe it should be — we are prepared to support the Company with the recruiting and nomination of new directors and executives, if necessary, to ensure that the Company fulfills its promise to patients, employees, business partners and stockholders. The uncompelling Merger Agreement Proposal before stockholders today appears to us to be the result of suboptimal timing and a flawed process, and the price appears to reflect near - term pessimism and market dynamics rather than the Company’s intrinsic value. We are confident that STAAR can deliver near - term value to stockholders far in excess of the $28 per share that Alcon is offering and that, in the long term, the Company can build upon that value as it delivers on the promise of its unique technology and assets. We oppose the Proposed Merger on that basis and urge other stockholders to join us in doing so by voting “ AGAINST ” the Merger Agreement Proposal on the GREEN Proxy Card . 1. See the Company’s Q1 2025 Earnings Call, available at https://investors.staar.com/~/media/Files/S/staar - surgical/investors/quarter